CN Patent

CN1665496B — Epa和dha在制备二级预防神经性疾患的药物中的用途

Assigned to Pronova Biopharma Norge AS · Expires 2010-05-05 · 16y expired

What this patent protects

本发明涉及n-3PUFA EPA和/或DHA在制备预防有脑部供血动脉粥样硬化症状的患者大脑损害的口服药物中的应用。

USPTO Abstract

本发明涉及n-3PUFA EPA和/或DHA在制备预防有脑部供血动脉粥样硬化症状的患者大脑损害的口服药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN1665496B
Jurisdiction
CN
Classification
—
Expires
2010-05-05
Drug substance claim
No
Drug product claim
No
Assignee
Pronova Biopharma Norge AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.